## Agnieszka Jankowska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4117352/publications.pdf

Version: 2024-02-01

933410 888047 21 294 10 17 citations g-index h-index papers 21 21 21 372 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Design and synthesis of new anilide and benzylamide derivatives as potential multifunctional ligands with procognitive and antidepressant activity. Postępy Polskiej Medycyny I Farmacji, 2022, 9, 1-8.	0.0	O
2	Pan-Phosphodiesterase Inhibitors Attenuate TGF- $\hat{l}^2$ -Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation. Pharmaceuticals, 2022, 15, 423.	3.8	4
3	Multifunctional Ligands with Glycogen Synthase Kinase 3 Inhibitory Activity as a New Direction in Drug Research for Alzheimer's Disease. Current Medicinal Chemistry, 2021, 28, 1731-1745.	2.4	9
4	Diabetic Theory in Anti-Alzheimer's Drug Research and Development. Part 2: Therapeutic Potential of cAMP-Specific Phosphodiesterase Inhibitors. Current Medicinal Chemistry, 2021, 28, 3535-3553.	2.4	2
5	A new class of 5-HT1A receptor antagonists with procognitive and antidepressant properties. Future Medicinal Chemistry, 2021, 13, 1497-1514.	2.3	2
6	Design and Synthesis of Novel Aminoalkanamides Targeting Neurodegeneration and Symptoms of Alzheimer's Disease. Current Medicinal Chemistry, 2021, 28, 6082-6094.	2.4	2
7	Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity. Bioorganic and Medicinal Chemistry Letters, 2021, 49, 128318.	2,2	7
8	Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents. Bioorganic Chemistry, 2021, 117, 105409.	4.1	11
9	Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A/5-HT7 receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity. European Journal of Medicinal Chemistry, 2020, 201, 112437.	5.5	19
10	A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF- $\hat{l}^2$ Signaling and Activation of cAMP/PKA Signaling. International Journal of Molecular Sciences, 2020, 21, 4008.	4.1	28
11	Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer's Disease. Current Medicinal Chemistry, 2020, 27, 5351-5373.	2.4	10
12	Diabetic Theory in Anti-Alzheimer's Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents. Current Medicinal Chemistry, 2020, 27, 6658-6681.	2.4	6
13	Novel phosphodiesterases inhibitors from the group of purine-2,6-dione derivatives as potent modulators of airway smooth muscle cell remodelling. European Journal of Pharmacology, 2019, 865, 172779.	3.5	13
14	Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies. Current Medicinal Chemistry, 2019, 26, 4885-4913.	2.4	7
15	Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia. Current Drug Targets, 2019, 20, 1652-1669.	2.1	10
16	Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT 7 receptor agents with antidepressant activity. European Journal of Medicinal Chemistry, 2018, 147, 102-114.	5.5	16
17	Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2018, 146, 381-394.	5.5	37
18	Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain. European Journal of Medicinal Chemistry, 2018, 158, 517-533.	5 <b>.</b> 5	27

#	Article	IF	CITATIONS
19	Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer's Disease Therapy: Advances in Chemical and Biological Research. Current Medicinal Chemistry, 2018, 25, 2045-2067.	2.4	20
20	Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research. Current Drug Targets, 2018, 20, 122-143.	2.1	23
21	PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research. Current Medicinal Chemistry, 2017, 24, 673-700.	2.4	41